|
|
| MRD / Regn No. |
: THBC\23-24\01479 |
Date |
: 09/06/2026 |
| Patient Name |
: Krishnamurthy R |
Age & Gender |
: 66 Yrs. / Male |
| Contact No. |
: 9821110898 |
UHID |
: |
| Ht / Wt / BMI |
: |
BP S / BP D |
: |
| Allergies |
: NONE |
Referred By |
: |
| |
|
| Problem
List |
: |
T2DM (16/Apr/2016) | HTN (16/Apr/2018) | |
|
Subjective |
: |
T2DM-5-6 YRS,HTN - 5 YRS,TINNITUS - ACCLIMATIZED,T2DM- 14YRS/ DYSLIPIDEMIA/ IHD,AFRAID TO WALK AS PREVIOUSLY HAD LEG PAIN |
|
Objective |
: |
JUN-2026 REPORTS,ACR-203.69,HB-14.7,ALT-27.98/ AST-24.11,CR-0.85,EGFR-95.83,TC-97.16/ TG-225.06/ LDL-32.02/ HDL-20.13,VITB12-197,VITD-30.64,T3-78.2/ T4-7.4/ TSH-2.062,HBA1C-7.7%,FBS-158.8/ PPBS-173.3 |
|
Plan |
: |
TO CHECK FBS / PPBS / HBA1C IN 1ST WEEK OF APRIL - IF HBA1C DROPS BY ALTEAST 1% - WILL WAIT WITH SAME MEDS TILL JUNE APPT,IF FBS STILL HIGH - CAN CONSIDER LIPAGLYN WHICH WILL ADDRESS BOTH FBS AND TG |
|
|
|
S# |
Generic (Trade) Name |
Route |
Dosage |
Usage |
Duration |
|
1 |
ROZAVEL F 20 |
ORAL |
0-0-1 |
AD
|
6 MTHS |
|
|
2 |
CARDACE AM 5 |
ORAL |
0-0-1 |
AFTER DINNER
|
6 MTHS |
|
|
3 |
ASPIRIN EC 150 MG
ECOSPRIN 150 |
ORAL |
0-1-0 |
AL
|
6 MTHS |
|
|
4 |
METPURE XL 25 MG |
ORAL |
1-0-0 |
BBF
|
6 MTHS |
|
|
5 |
VIT B12
NERVIHENZ |
ORAL |
0-1-0 |
EVERY SAT AND SUNDAY
|
6 MTHS |
|
|
6 |
PREGALIN X SR 75 |
|
0-0-1 |
7 PM
|
3 MONTHS |
|
|
7 |
ROBINAXOL D |
ORALLY TWICE DAILY AFTER FOOD |
`1-0-1 |
|
7 DAYS |
|
|
8 |
ESYS 40 |
|
1-0-0 |
|
7 DAYS |
|
|
9 |
NIZER GEL |
|
|
|
|
|
|
10 |
UDAPA TRIO 10/100 / 1000 MG |
ORAL |
1-0-0 |
BBF
|
6 MTHS |
|
|
11 |
TABLET CLOPILET
CLOPIDOGREL 75 MG |
ORAL |
0-0-1 |
AD
|
6 MTHS |
|
|
12 |
GLYCINORM M 60 OD |
ORAL |
0-1-1 |
BL / BD
|
6 MTHS |
|
|
| |
|
|
|
| Refill :
0 / Substitution: |
|
|
| Education |
: IF LOW SUGARS (<70 MG/DL),TAKE 1 TBSP(15GMS) GLUCOSE POWDER. CHECK AGAIN AFTER 15 MINS IF >100 CAN GIVE A PROTEIN MEAL. |
| Next Visit |
: 26/Jun/2026 |
| Tests Suggested For Next Visit |
: HBA1C / FBS / PPBS - 1ST WEEK OF APRIL,SEE ME IN 4 MTHS - FBS / PPBS / HBA1C / LIPID PROFILE |
| |
|
| |
|
|
